193 related articles for article (PubMed ID: 33484165)
1. The contributions of metabolomics in the discovery of new therapeutic targets in Alzheimer's disease.
Altiné-Samey R; Antier D; Mavel S; Dufour-Rainfray D; Balageas AC; Beaufils E; Emond P; Foucault-Fruchard L; Chalon S
Fundam Clin Pharmacol; 2021 Jun; 35(3):582-594. PubMed ID: 33484165
[TBL] [Abstract][Full Text] [Related]
2. Status of Metabolomic Measurement for Insights in Alzheimer's Disease Progression-What Is Missing?
Yin C; Harms AC; Hankemeier T; Kindt A; de Lange ECM
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902391
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the application of metabolomics to Alzheimer's Disease.
Trushina E; Mielke MM
Biochim Biophys Acta; 2014 Aug; 1842(8):1232-9. PubMed ID: 23816564
[TBL] [Abstract][Full Text] [Related]
4. Urine metabolomics analysis for biomarker discovery and detection of jaundice syndrome in patients with liver disease.
Wang X; Zhang A; Han Y; Wang P; Sun H; Song G; Dong T; Yuan Y; Yuan X; Zhang M; Xie N; Zhang H; Dong H; Dong W
Mol Cell Proteomics; 2012 Aug; 11(8):370-80. PubMed ID: 22505723
[TBL] [Abstract][Full Text] [Related]
5. High-Throughput Metabolomics for Discovering Potential Metabolite Biomarkers and Metabolic Mechanism from the APPswe/PS1dE9 Transgenic Model of Alzheimer's Disease.
Yu J; Kong L; Zhang A; Han Y; Liu Z; Sun H; Liu L; Wang X
J Proteome Res; 2017 Sep; 16(9):3219-3228. PubMed ID: 28753016
[TBL] [Abstract][Full Text] [Related]
6. Serum metabolomic profiling in patients with Alzheimer disease and amnestic mild cognitive impairment by GC/MS.
Sun C; Gao M; Wang F; Yun Y; Sun Q; Guo R; Yan C; Sun X; Li Y
Biomed Chromatogr; 2020 Sep; 34(9):e4875. PubMed ID: 32384189
[TBL] [Abstract][Full Text] [Related]
7. Characterizing Alzheimer's disease through metabolomics and investigating anti-Alzheimer's disease effects of natural products.
Yi L; Liu W; Wang Z; Ren D; Peng W
Ann N Y Acad Sci; 2017 Jun; 1398(1):130-141. PubMed ID: 28632966
[TBL] [Abstract][Full Text] [Related]
8. Integrated network pharmacology analysis and serum metabolomics to reveal the cognitive improvement effect of Bushen Tiansui formula on Alzheimer's disease.
Zhang Z; Yi P; Yang J; Huang J; Xu P; Hu M; Zhang C; Wang B; Peng W
J Ethnopharmacol; 2020 Mar; 249():112371. PubMed ID: 31683034
[TBL] [Abstract][Full Text] [Related]
9. Metabolomic Alterations in the Blood and Brain in Association with Alzheimer's Disease: Evidence from in vivo to Clinical Studies.
Sriwichaiin S; Chattipakorn N; Chattipakorn SC
J Alzheimers Dis; 2021; 84(1):23-50. PubMed ID: 34511504
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation of multiple metabolic networks related to brain transmethylation and polyamine pathways in Alzheimer disease: A targeted metabolomic and transcriptomic study.
Mahajan UV; Varma VR; Griswold ME; Blackshear CT; An Y; Oommen AM; Varma S; Troncoso JC; Pletnikova O; O'Brien R; Hohman TJ; Legido-Quigley C; Thambisetty M
PLoS Med; 2020 Jan; 17(1):e1003012. PubMed ID: 31978055
[TBL] [Abstract][Full Text] [Related]
11. Serum Metabolomic and Lipidomic Profiling Reveals Novel Biomarkers of Efficacy for Benfotiamine in Alzheimer's Disease.
Bhawal R; Fu Q; Anderson ET; Gibson GE; Zhang S
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947984
[TBL] [Abstract][Full Text] [Related]
12. Metabolomic-guided discovery of Alzheimer's disease biomarkers from body fluid.
Enche Ady CNA; Lim SM; Teh LK; Salleh MZ; Chin AV; Tan MP; Poi PJH; Kamaruzzaman SB; Abdul Majeed AB; Ramasamy K
J Neurosci Res; 2017 Oct; 95(10):2005-2024. PubMed ID: 28301062
[TBL] [Abstract][Full Text] [Related]
13. Metabolic characterization of diabetic retinopathy: An
Jin H; Zhu B; Liu X; Jin J; Zou H
J Pharm Biomed Anal; 2019 Sep; 174():414-421. PubMed ID: 31212142
[TBL] [Abstract][Full Text] [Related]
14. Systemic and central nervous system metabolic alterations in Alzheimer's disease.
van der Velpen V; Teav T; Gallart-Ayala H; Mehl F; Konz I; Clark C; Oikonomidi A; Peyratout G; Henry H; Delorenzi M; Ivanisevic J; Popp J
Alzheimers Res Ther; 2019 Nov; 11(1):93. PubMed ID: 31779690
[TBL] [Abstract][Full Text] [Related]
15. Reduced Hippocampal Glutamate and Posterior Cingulate N-Acetyl Aspartate in Mild Cognitive Impairment and Alzheimer's Disease Is Associated with Episodic Memory Performance and White Matter Integrity in the Cingulum: A Pilot Study.
Wong D; Atiya S; Fogarty J; Montero-Odasso M; Pasternak SH; Brymer C; Borrie MJ; Bartha R
J Alzheimers Dis; 2020; 73(4):1385-1405. PubMed ID: 31958093
[TBL] [Abstract][Full Text] [Related]
16. UHPLC-QTOF/MS-based metabolomics investigation for the protective mechanism of Danshen in Alzheimer's disease cell model induced by Aβ
Zhang M; Liu Y; Liu M; Liu B; Li N; Dong X; Hong Z; Chai Y
Metabolomics; 2019 Jan; 15(2):13. PubMed ID: 30830431
[TBL] [Abstract][Full Text] [Related]
17. Next-generation biomarker discovery in Alzheimer's disease using metabolomics - from animal to human studies.
Hurtado MO; Kohler I; de Lange EC
Bioanalysis; 2018 Sep; 10(18):1525-1546. PubMed ID: 30198770
[TBL] [Abstract][Full Text] [Related]
18. Integrative metabolomics science in Alzheimer's disease: Relevance and future perspectives.
Lista S; González-Domínguez R; López-Ortiz S; González-Domínguez Á; Menéndez H; Martín-Hernández J; Lucia A; Emanuele E; Centonze D; Imbimbo BP; Triaca V; Lionetto L; Simmaco M; Cuperlovic-Culf M; Mill J; Li L; Mapstone M; Santos-Lozano A; Nisticò R
Ageing Res Rev; 2023 Aug; 89():101987. PubMed ID: 37343679
[TBL] [Abstract][Full Text] [Related]
19. Toward a predictive model of Alzheimer's disease progression using capillary electrophoresis-mass spectrometry metabolomics.
Ibáñez C; Simó C; Martín-Álvarez PJ; Kivipelto M; Winblad B; Cedazo-Mínguez A; Cifuentes A
Anal Chem; 2012 Oct; 84(20):8532-40. PubMed ID: 22967182
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
